Prognostic Significance of C-reactive Protein-to-prealbumin Ratio in Patients with Esophageal Cancer.
C-reactive protein-to-prealbumin ratio
esophageal cancer
esophagectomy
inflammatory marker
prognosis
Journal
Yonago acta medica
ISSN: 0513-5710
Titre abrégé: Yonago Acta Med
Pays: Japan
ID NLM: 0414002
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
23
10
2019
accepted:
25
11
2019
entrez:
12
3
2020
pubmed:
12
3
2020
medline:
12
3
2020
Statut:
epublish
Résumé
The prognostic value of combination of C-reactive protein and prealbumin (CRP/PAlb) in esophageal cancer remains unclear. We enrolled 167 esophageal cancer patients who underwent curative esophagectomy. Univariate and multivariate analyses were performed to determine the prognostic significance of various markers, including CRP-to-albumin (CRP/Alb) ratio, modified Glasgow prognostic score, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and prognostic nutritional index. Receiver operating characteristic analysis revealed the optimal cut-off value of each inflammatory factor, and CRP/PAlb ratio had the greatest discriminative power in predicting recurrence-free survival (RFS) among the examined measures (AUC 0.668). The 5-year overall survival and RFS rates were significantly lower in patients with high CRP/PAlb ratio than in those with low CRP/PAlb ratio ( CRP/PAlb ratio was useful for predicting the prognosis of esophageal cancer patients.
Sections du résumé
BACKGROUND
BACKGROUND
The prognostic value of combination of C-reactive protein and prealbumin (CRP/PAlb) in esophageal cancer remains unclear.
METHODS
METHODS
We enrolled 167 esophageal cancer patients who underwent curative esophagectomy. Univariate and multivariate analyses were performed to determine the prognostic significance of various markers, including CRP-to-albumin (CRP/Alb) ratio, modified Glasgow prognostic score, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and prognostic nutritional index.
RESULTS
RESULTS
Receiver operating characteristic analysis revealed the optimal cut-off value of each inflammatory factor, and CRP/PAlb ratio had the greatest discriminative power in predicting recurrence-free survival (RFS) among the examined measures (AUC 0.668). The 5-year overall survival and RFS rates were significantly lower in patients with high CRP/PAlb ratio than in those with low CRP/PAlb ratio (
CONCLUSION
CONCLUSIONS
CRP/PAlb ratio was useful for predicting the prognosis of esophageal cancer patients.
Identifiants
pubmed: 32158328
doi: 10.33160/yam.2020.02.002
pii: 2020.02.002
pmc: PMC7028532
doi:
Types de publication
Journal Article
Langues
eng
Pagination
8-19Informations de copyright
©2020 Tottori University Medical Press.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Mol Clin Oncol. 2017 Dec;7(6):1073-1078
pubmed: 29285377
Tumour Biol. 2015 May;36(5):3389-97
pubmed: 25527156
Oncotarget. 2016 Sep 20;7(38):62123-62132
pubmed: 27557504
Gastric Cancer. 2019 May;22(3):536-545
pubmed: 30377862
Dis Esophagus. 2017 Dec 1;30(12):1-5
pubmed: 28881893
Oncotarget. 2017 Oct 20;8(61):103535-103542
pubmed: 29262582
Exp Ther Med. 2011 Sep;2(5):879-885
pubmed: 22977592
Ann Surg Oncol. 2015 Dec;22(13):4432-7
pubmed: 25862583
BMC Cancer. 2015 May 02;15:350
pubmed: 25934640
Nihon Geka Gakkai Zasshi. 1984 Sep;85(9):1001-5
pubmed: 6438478
Nutr Hosp. 2009 Mar-Apr;24(2):241-2
pubmed: 19593499
N Engl J Med. 2012 May 31;366(22):2074-84
pubmed: 22646630
Oncotarget. 2017 Sep 20;8(48):84506-84514
pubmed: 29137443
Ann Surg. 2011 Apr;253(4):689-98
pubmed: 21475008
Ann Surg Oncol. 2011 Nov;18(12):3338-52
pubmed: 21537872
J Oncol. 2019 Jul 14;2019:4359103
pubmed: 31379941
Ann Surg Oncol. 2018 Oct;25(11):3288-3299
pubmed: 30019304
Oncology. 2016;90(6):321-6
pubmed: 27225990
Jpn J Clin Oncol. 2015 Jan;45(1):61-6
pubmed: 25341546
Anticancer Res. 2018 Aug;38(8):4735-4746
pubmed: 30061243
Clin Med (Lond). 2009 Feb;9(1):30-3
pubmed: 19271597
Br J Cancer. 2006 Mar 13;94(5):637-41
pubmed: 16479253
Dis Esophagus. 2016 Jan;29(1):79-85
pubmed: 25410116
J Surg Oncol. 2019 May;119(6):794-800
pubmed: 30648280
Am J Transplant. 2013 Jun;13(6):1549-56
pubmed: 23601159
Future Oncol. 2010 Jan;6(1):149-63
pubmed: 20021215
World J Surg. 2012 Dec;36(12):2853-7
pubmed: 22948197
Exp Ther Med. 2018 Jul;16(1):321-327
pubmed: 29896256
Ann Surg Oncol. 2014 Feb;21(2):575-82
pubmed: 24201746
Ann Surg. 2015 Aug;262(2):280-5
pubmed: 25211269
Sci Rep. 2017 Nov 30;7(1):16609
pubmed: 29192175
Contemp Oncol (Pozn). 2013;17(3):276-80
pubmed: 24596514
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
HPB (Oxford). 2019 Feb;21(2):157-166
pubmed: 30082212
N Engl J Med. 2003 Dec 4;349(23):2241-52
pubmed: 14657432
BMC Cancer. 2013 Nov 11;13:539
pubmed: 24206575
Eur J Cancer. 2011 Nov;47(17):2633-41
pubmed: 21724383
Nature. 2002 Dec 19-26;420(6917):860-7
pubmed: 12490959
Br J Cancer. 2012 Sep 4;107(6):988-93
pubmed: 22878374
Gynecol Oncol. 2007 Jul;106(1):128-31
pubmed: 17466363
Lancet Oncol. 2015 Sep;16(9):1090-1098
pubmed: 26254683
Pathologe. 2010 Sep;31(5):331-2
pubmed: 20703480
World J Gastroenterol. 2015 May 14;21(18):5591-7
pubmed: 25987784